SCND SCIENTIFIC INDUSTRIES INC
Laboratory Analytical Instruments · OTC · SEC CIK 87802 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.6%
TTM net income YoY-244.6%
TTM EPS YoY-208.3%
Revenue 3-yr CAGR-19.6%
Net income 3-yr CAGR—
Margins
Gross margin31.3%
Operating margin-116.3%
Net margin-75.1%
FCF margin-110.6%
EBITDA margin-110.8%
Returns
ROE-40.4%
ROA-33.5%
ROIC (approx.)-56.1%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets20.7%
Debt / equity0.00x
Current ratio6.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio15.4%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-06-30 | FY20202021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.05M | $4.80M | $11.11M | $11.40M | $9.78M |
| Cost of revenue | $3.75M | $2.79M | $6.01M | $5.66M | $4.80M |
| Gross profit | $1.30M | $2.01M | $5.10M | $5.74M | $4.98M |
| R&D expense | $2.49M | $2.90M | $3.57M | $2.87M | $1.62M |
| SG&A expense | $3.27M | $4.12M | $5.42M | $5.82M | $4.03M |
| Operating income | -$7.89M | -$8.22M | -$9.26M | -$11.54M | -$4.71M |
| Pretax income | -$1.78M | -$8.02M | -$9.09M | -$11.28M | -$4.05M |
| Income tax | $4,600 | $0 | $0 | $2.39M | -$1.15M |
| Net income | -$1.22M | -$6.45M | -$9.09M | -$13.67M | -$3.67M |
| EBITDA | -$7.28M | -$7.47M | -$8.51M | -$10.86M | -$4.46M |
| EPS (basic) | — | — | — | — | -1.00 |
| EPS (diluted) | -0.11 | -0.61 | -1.27 | — | -1.00 |
| Weighted avg. shares (diluted) | 11.34M | 10.50M | 10.15M | 6.64M | 3.19M |
| Banking | |||||
| Provision for credit losses | — | — | $0 | $0 | $4,000 |
| Balance sheet | |||||
| Cash & equivalents | $955,000 | $587,900 | $796,100 | $2.97M | $9.68M |
| Short-term investments | $5.71M | — | — | — | — |
| Receivables | $865,800 | $581,900 | $1.16M | $1.50M | $1.29M |
| Inventory | $1.75M | $2.06M | $4.88M | $4.70M | $2.98M |
| Current assets | $10.39M | $8.29M | $12.34M | $16.27M | $18.43M |
| PP&E, net | $690,900 | $796,300 | $1.08M | $1.01M | $412,600 |
| Goodwill | $115,300 | $115,300 | $115,300 | $115,300 | $4.40M |
| Intangibles | $103,500 | $752,300 | $1.25M | $2.08M | $2.56M |
| Total assets | $12.61M | $11.56M | $16.73M | $21.01M | $29.01M |
| Current liabilities | $1.35M | $1.75M | $1.84M | $2.23M | $2.29M |
| Total liabilities | $1.94M | $2.44M | $2.85M | $3.47M | $2.78M |
| Shareholders' equity | $10.66M | $9.12M | $13.89M | $17.54M | $26.22M |
| Shares outstanding | 11.93M | 10.50M | 10.15M | 7.00M | 6.46M |
| Cash flow statement | |||||
| Operating cash flow | -$8.15M | -$3.05M | -$6.16M | -$5.19M | -$3.58M |
| Capital expenditure | $63,200 | $98,900 | $131,700 | $757,600 | $198,700 |
| Free cash flow | -$8.21M | -$3.15M | -$6.29M | -$5.95M | -$3.78M |
| Investing cash flow | $3.83M | $2.87M | -$735,100 | -$3.75M | -$10.88M |
| Financing cash flow | $1.95M | $645,700 | $5.75M | $2.31M | $16.59M |
| Depreciation & amortization | $610,000 | $750,700 | $754,000 | $688,200 | $251,500 |
| Stock-based compensation | $520,700 | $1.17M | $2.24M | $2.35M | $2.11M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.